{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:28:48Z","timestamp":1767983328118,"version":"3.49.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The disease course of COVID-19 in patients with immunodeficiencies is unclear, as well as the optimal therapeutic strategy. We report a case of a 37-year old male with common variable immunodeficiency disorder and a severe SARS-CoV-2 infection. After administration of convalescent plasma, the patient\u2019s condition improved rapidly. Despite clinical recovery, viral RNA remained detectable up to 60 days after onset of symptoms. We propose that convalescent plasma might be considered as a treatment option in patients with CVID and severe COVID-19.\u00a0In addition,\u00a0in patients with immunodeficiencies, a different clinical course is possible, with prolonged viral shedding.<\/jats:p>","DOI":"10.3389\/fimmu.2020.596761","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T05:55:17Z","timestamp":1605851717000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19"],"prefix":"10.3389","volume":"11","author":[{"given":"Karel F. A.","family":"Van Damme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nele","family":"Van Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"De Leeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozefien","family":"Declercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Bosteels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastiaan","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delfien","family":"Bogaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Bosteels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levi","family":"Hoste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Naesens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Weiskopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Depuydt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Van Braeckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomeen","family":"Haerynck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart N.","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12607","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.01.20139857","article-title":"Convalescent Plasma for COVID-19. A randomized clinical trial","author":"Gharbharan","year":"2020","journal-title":"medRxiv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","author":"Soresina","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.04.033","article-title":"The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019","volume":"125","author":"Fill","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.026","article-title":"How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection\u00a0? A systematic review","volume":"81","author":"Minotti","year":"2020","journal-title":"J Infect"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04520-x","article-title":"Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Bosteels","year":"2020","journal-title":"Trials"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: Possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123158","article-title":"Anti\u2013spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.01.20139857","article-title":"Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses","volume":"4","author":"Hoepel","year":"2020","journal-title":"MedRxiv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600.pub2","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"7","author":"Piechotta","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in Immunocompromised Hosts: What We Know So Far","author":"Fung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"eabd0110","DOI":"10.1126\/sciimmunol.abd0110","article-title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19","volume":"5","author":"Roschewski","year":"2020","journal-title":"Sci Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2015-103690","article-title":"Genes associated with common variable immunodeficiency: one diagnosis to rule them all","volume":"53","author":"Bogaert","year":"2016","journal-title":"J Med Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.596761\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T05:55:20Z","timestamp":1605851720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.596761\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2020.596761"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.596761","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"article-number":"596761"}}